113 related articles for article (PubMed ID: 30254823)
1. Re-expression of the p53 Gene by Inhibiting the Mdm-2 Receptor in Wild-type p53 Tumors for the Treatment of Glioblastoma: A Mini Review.
Ahmed SI; Bareeqa SB; Samar SS
Cureus; 2018 Jul; 10(7):e3034. PubMed ID: 30254823
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer.
Sjöström J; Blomqvist C; Heikkilä P; Boguslawski KV; Räisänen-Sokolowski A; Bengtsson NO; Mjaaland I; Malmström P; Ostenstadt B; Bergh J; Wist E; Valvere V; Saksela E
Clin Cancer Res; 2000 Aug; 6(8):3103-10. PubMed ID: 10955790
[TBL] [Abstract][Full Text] [Related]
4. Lead Optimization of 2-Phenylindolylglyoxylyldipeptide Murine Double Minute (MDM)2/Translocator Protein (TSPO) Dual Inhibitors for the Treatment of Gliomas.
Daniele S; La Pietra V; Barresi E; Di Maro S; Da Pozzo E; Robello M; La Motta C; Cosconati S; Taliani S; Marinelli L; Novellino E; Martini C; Da Settimo F
J Med Chem; 2016 May; 59(10):4526-38. PubMed ID: 27050782
[TBL] [Abstract][Full Text] [Related]
5. mdm-2 expression correlates with wild-type p53 status in esophageal adenocarcinoma.
Soslow RA; Altorki NK; Yang G; Xie D; Yang CS
Mod Pathol; 1999 Jun; 12(6):580-6. PubMed ID: 10392633
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of mdm-2 expression in Meth A tumor cells tolerating wild-type p53.
Otto A; Deppert W
Oncogene; 1993 Sep; 8(9):2591-603. PubMed ID: 8361769
[TBL] [Abstract][Full Text] [Related]
7. Transition from in situ to invasive testicular germ cell neoplasia is associated with the loss of p21 and gain of mdm-2 expression.
Datta MW; Macri E; Signoretti S; Renshaw AA; Loda M
Mod Pathol; 2001 May; 14(5):437-42. PubMed ID: 11353054
[TBL] [Abstract][Full Text] [Related]
8. The mdm-2 oncogene is translocated and overexpressed in a murine plasmacytoma cell line expressing wild-type p53.
Berberich S; Cole M
Oncogene; 1994 May; 9(5):1469-72. PubMed ID: 8152809
[TBL] [Abstract][Full Text] [Related]
9. Uniform MDM2 overexpression in a panel of glioblastoma multiforme cell lines with divergent EGFR and p53 expression status.
Halatsch ME; Schmidt U; Unterberg A; Vougioukas VI
Anticancer Res; 2006; 26(6B):4191-4. PubMed ID: 17201132
[TBL] [Abstract][Full Text] [Related]
10. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
[TBL] [Abstract][Full Text] [Related]
11. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
[TBL] [Abstract][Full Text] [Related]
12. P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia.
Johnston JB; Daeninck P; Verburg L; Lee K; Williams G; Israels LG; Mowat MR; Begleiter A
Leuk Lymphoma; 1997 Aug; 26(5-6):435-49. PubMed ID: 9389352
[TBL] [Abstract][Full Text] [Related]
13. Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene.
Chen J; Lin J; Levine AJ
Mol Med; 1995 Jan; 1(2):142-52. PubMed ID: 8529093
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and prognostic significance of murine double minute protein-2 overexpression and P53 gene mutations in childhood acute lymphoblastic leukemia.
Hendy OM; Elghannam DM; El-Sharnouby JA; Goda EF; El-Ashry R; Al-Tonbary Y
Egypt J Immunol; 2008; 15(1):93-100. PubMed ID: 20306673
[TBL] [Abstract][Full Text] [Related]
15. Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells.
Daniele S; Costa B; Zappelli E; Da Pozzo E; Sestito S; Nesi G; Campiglia P; Marinelli L; Novellino E; Rapposelli S; Martini C
Sci Rep; 2015 Apr; 5():9956. PubMed ID: 25898313
[TBL] [Abstract][Full Text] [Related]
16. MDM-2 oncoprotein overexpression in laryngeal squamous cell carcinoma: association with wild-type p53 accumulation.
Pruneri G; Pignataro L; Carboni N; Luminari S; Capaccio P; Neri A; Buffa R
Mod Pathol; 1997 Aug; 10(8):785-92. PubMed ID: 9267820
[TBL] [Abstract][Full Text] [Related]
17. Tolerance of high levels of wild-type p53 in transformed epithelial cells dependent on auto-regulation by mdm-2.
Blaydes JP; Gire V; Rowson JM; Wynford-Thomas D
Oncogene; 1997 Apr; 14(15):1859-68. PubMed ID: 9150392
[TBL] [Abstract][Full Text] [Related]
18. Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme.
Kawasoe T; Takeshima H; Yamashita S; Mizuguchi S; Fukushima T; Yokogami K; Yamasaki K
J Neurosurg; 2015 Feb; 122(2):317-23. PubMed ID: 25415071
[TBL] [Abstract][Full Text] [Related]
19. Supratentorial glioblastoma in adults: identification of subsets and their clinical correlation.
Sarkar C; Sinha S; Sharma MC; Kumar R; Mehta VS
Brain Tumor Pathol; 2004; 21(1):7-12. PubMed ID: 15696962
[TBL] [Abstract][Full Text] [Related]
20. An accelerated senescence response to radiation in wild-type p53 glioblastoma multiforme cells.
Quick QA; Gewirtz DA
J Neurosurg; 2006 Jul; 105(1):111-8. PubMed ID: 16871885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
